Document is current

Article History

Accepted: 5 December 2020

First Online: 13 January 2021

Declarations

:

: Jazz Pharmaceuticals funded this study; provided medical writing assistance and editorial assistance in formatting, proofreading, copyediting, and fact checking; and open access to the published article.

: Michael J. Strunc has received research funding from Jazz Pharmaceuticals, has received honoraria for grand rounds, and has served on the speakers’ bureau for Jazz Pharmaceuticals and has provided expert testimony. Jed Black is a part-time employee of Jazz Pharmaceuticals and shareholder of Jazz Pharmaceuticals plc. Prasheel Lillaney, Sherice Mills, and Shay Bujanover are employees of Jazz Pharmaceuticals who, in the course of their employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Judi Profant is a former employee of Jazz Pharmaceuticals who, in the course of her employment, received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. Michael J. Thorpy has received research/grant support and consultancy fees from Jazz Pharmaceuticals, Axsome Therapeutics, Balance Therapeutics, Avadel Pharmaceuticals, Takeda Pharmaceuticals, Harmony Biosciences, and Suven Life Sciences.

: Not applicable.

: Not applicable.

: Not applicable.

: All relevant data are provided within the manuscript and supporting files.

: Not applicable.

: Conceptualization: Prasheel Lillaney, Jed Black. Methodology: Prasheel Lillaney, Jed Black. Formal analysis and investigation: Prasheel Lillaney. Writing, review, and editing: Prasheel Lillaney, Jed Black. Supervision: Jed Black.